Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

November 18, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Covid Update: Moderna Vaccine on the Horizon!

University of Hyderabad Research Associate | Assistant Recruitment

Bluetongue Disease: a viral disease

Covid Update: Moderna Vaccine on the Horizon!
  • BiotechToday
  • India
  • World

Covid Update: Moderna Vaccine on the Horizon!

bioxone October 20, 2020October 20, 2020

Chitra Roy, University of Calcutta

An American biotechnology company ‘Moderna’, based in Cambridge, Massachusetts focuses on the discovery and development of drugs in addition to vaccine technologies. They exclusively use messenger RNA (mRNA) therapeutics and designs vaccines to create a completely new generation of transformative medicines. Against COVID-19, Moderna has developed its mRNA vaccine candidate known as mRNA-1273 and began its Phase 3 study from 27th of July,2020. The Phase 3 trial is also known as COVE- Coronavirus Efficacy study where 30,000 individuals in the United States were given the mRNA-1273 dosage of 100 µg. In this trial, half of the subject candidates received the vaccine and the other half received a placebo and their study focused on how many among them would develop symptomatic COVID-19. Their primary endpoint is the prevention of symptomatic COVID-19. And their secondary endpoints include to prevent severe COVID-19 cases where there is a need for hospitalization and also, to prevent any infection by SARS-CoV-2 (the virus that causes COVID-19) regardless of symptomology.

Currently, Moderna is expecting the interim results of its Phase 3 trials by next month. As reported by their Chief Executive Stephane Bancel during The Wall Street Journal’s annual Tech Live Conference, that, if the results are in favour of their vaccine based on the positive interim results, the US government can authorise the ‘emergency use’ of the mRNA-1273 vaccine in December. Also mentioning that if it gets longer to generate sufficient interim results, the government authorization of their vaccine might not occur until early next year. Their first analysis will occur in November but it might become difficult to predict the exact week of November because it will depend on the number of symptomatic cases and on the number of people getting severely affected which might vary.

Presently, Moderna is developing one of the leading coronavirus vaccines. Meanwhile, another vaccine is co-developed by U.S. drugmaker Pfizer Inc and Germany’s BioNTech. In the previous week, Pfizer announced that the COVID-19 vaccine which is under their development can be filed in late November for U.S authorization. Pfizer Chief Executive Albert Bourla stated that if positive data is received by the third week of November, only then Pfizer will apply for Emergency Authorisation Use in the U.S. 

Moderna in the previous month also announced its willingness to get real-time reviews of their experimental ongoing COVID-19 vaccine. This month The European Medicines Agency has launched real-time reviews of COVID-19 vaccines developed by Pfizer and BioNTech. 

Hope, for the COVID-19 vaccine, is on the horizon!

Also read: Disruption of mutp53 stability might hold the key in this long and hard battle against Cancer

Reference: https://www.livemint.com/science/health/covid-vaccine-moderna-targets-emergency-approval-in-december-11603165328904.html

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged coronavirus news coronavirus update coronavirus vaccine Covid vaccine COVID-19 moderna moderna mRNA vaccine moderna vaccine mRNA vaccine mRNA vaccine covid vaccination VACCINE vaccine status

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Biotechnopedia
  • DNA-Tales

Bluetongue Disease: a viral disease

bioxone October 20, 2020

Ankita Chattopadhyay, Amity University Kolkata Bluetongue is a viral disease affecting sheep, cattle, deer, and goats. It is a non-contagious, insect-borne disease to which all species of ruminants are susceptible. Studies show that sheep are mostly the victims but the cattle are the main mammal reservoir of the virus. This virus is a notifiable disease […]

Bluetongue

Related Post

  • BiotechToday
  • World

WORLD INTELLECTUAL PROPERTY DAY! Let’s celebrate honest hard work

bioxone April 26, 2021April 26, 2021

Camelia Bhattacharyya, Amity University Kolkata Maxine Hong Kingston once quoted, “In the time of destruction, create something” and to create is the motto of most intellectual minds. There wouldn’t have been civilizations dawning out of nowhere if the human minds were at rest and wouldn’t have thought to do something “out of the box”. But […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Investigation of eDNA Genomics of Bear Fossils

bioxone April 25, 2021April 25, 2021

Thota Kanishka Rao, Amity University Kolkata Investigation of old environmental DNA (eDNA) has altered our capacity to portray biological communities in reality, by taking into consideration equal sequencing of DNA from every trophic level. Be that as it may, because ecological samples contain sparse and fragmented information from various individuals, and regularly contain firmly related […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • FEATURED
  • Latest
  • World

COVID UPDATE: COVID elixir by Oxford is unsafe? Trials put on hold yet again!

bioxone September 9, 2020September 9, 2020

-Binayak Das, Team bioXone The highly-awaited trials for the Covid-19 vaccine formulation by Oxford have yet again been put on hold for a second time this year. The reason behind this has to do with certain safety concerns, as informed to Stat News, on Tuesday. This measure was taken by AstraZeneca Plc. right after they observed […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy